 |
Alpha-1 Adrenergic Blockers
Mechanism of action |
| Act at post-synaptic alpha-1 receptors to produce arteriole and venous vasodilation |
alfuzosin (Uroxatral ® ) |
|
BPH: 10 mg orally once daily. [ Supplied: 10mg extended release tablet.] |
doxazosin (Cardura ® ) |
|
BPH: initial, 1 mg orally once daily. May increase dose at 1-2
week intervals. Maintenance: 1-8 mg orally once daily. CHF: 1-16 mg
orally once daily. Hypertension: initial, 1 mg orally once daily.
Maintenance, 1-16 mg po once daily. [Supplied 1 mg, 2 mg, 4 mg, 8 mg tablets] |
prazosin (Minipress ® ) |
|
HTN: Initial dose 1 mg bid to tid. Usual range: 6
mg to 15 mg daily given in divided doses. Doses higher than 20 mg
usually do not increase efficacy, however a few patients may benefit
from further increases up to a daily dose of 40 mg given in divided
doses. [Supplied: 1, 2, 5mg capsules] |
tamsulosin ( Flomax ® ) |
|
BPH: 0.4 mg orally once daily, given 30 minutes
after a meal. May increase dose after 2 to 4 weeks to a maximum of 0.8
mg/day. [Supplied: 0.4 mg capsule] |
terazosin (Hytrin ® ) |
|
Adult (usual) - (BPH): initial, 1 mg orally qhs.
Maintenance, 1-10 mg orally once daily (Maximum: 20 mg/day).
Hypertension (HTN): initial, 1 mg po qhs. Maintenance (HTN): 1-5 mg po
qd - bid. Maximum: 20-40 mg/day [Supplied 1, 2, 5, 10 mg capsule] |
MDX: DOXAZOSIN-TO-TERAZOSIN CONVERSION |
| According to 1 study, dosage-conversion from doxazosin to terazosin results in similar or better control of symptoms in most (83%) patients with BENIGN PROSTATIC HYPERPLASIA (BPH). In this study, patients with BPH (n=69) were switched from doxazosin to terazosin according to the following protocol: doxazosin 1 milligram (mg) to terazosin 1 mg, 2 mg to 2 mg, 4 mg to 5 mg, 8 mg to 10 mg, 12 mg to 15 mg, and 16 mg to 20 mg. There were no significant differences in International Prostate Symptom Score (IPSS), blood pressure, pulse, or adverse effects before and after the conversion (p less than 0.05). |
|
|
Disclaimer |
|
Listed dosages are for - Adult patients ONLY. PLEASE READ THE
DISCLAIMER CAREFULLY BEFORE
ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE
TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.
GlobalRPH does not directly or indirectly practice medicine or provide
medical services and therefore assumes no liability whatsoever of any
kind for the information and data accessed through the Service or for
any diagnosis or treatment made in reliance thereon. David F. McAuley, Pharm.D., R.Ph. GlobalRPh Inc. |
| Disclaimer Contact Us Privacy Policy Website Search | We comply with the HONcode standard for health trustworthy information: Verify here. Copyright © 2007 GlobalRPh Inc. |
 |
 |